Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Personalization of thiopurine therapy : current recommendations and future perspectives
ID
Urbančič, Dunja
(
Author
),
ID
Pasha, Flaka
(
Author
),
ID
Šmid, Alenka
(
Author
),
ID
Mlinarič-Raščan, Irena
(
Author
)
PDF - Presentation file,
Download
(950,58 KB)
MD5: 2663CFB851AEFC3C327FC1F19CD88ABF
URL - Source URL, Visit
https://acta.pharmaceutica.farmaceut.org/wp-content/uploads/2024/09/35524.pdf
URL - Source URL, Visit
https://sciendo.com/article/10.2478/acph-2024-0030
Image galllery
Abstract
Despite great therapeutic advances in the field of biologics, small synthetic molecules such as thiopurines, including azathioprine, mercaptopurine, and thioguanine, remain an important therapeutic pillar in the treatment of inflammatory bowel disease, other autoimmune disorders, and cancer. This review presents the latest guidelines for thiopurine administration, highlighting the importance of individualized therapy guided by pharmacogenomics. It emphasizes dose adjustment based on nudix hydrolase 15 (NUDT15) and thiopurine S-methyltransferase (TPMT) genotype, alongside thiopurine S-methyltransferase activity and thiopurine metabolic profile. In addition, the article takes a critical look at emerging research in the field of thiopurine pharmacogenomics featuring novel genetic markers and technological developments in genetic testing. Finally, the potential of integrated approaches that combine genetic, metabolic, and clinical factors to further individualize thiopurine therapy is highlighted.
Language:
English
Keywords:
thiopurines
,
TPMT
,
NUDT15
,
personalized medicine
,
therapeutic drug monitoring
Work type:
Article
Typology:
1.02 - Review Article
Organization:
FFA - Faculty of Pharmacy
Publication status:
Published
Publication version:
Version of Record
Year:
2024
Number of pages:
Str. 355-381
Numbering:
Vol. 74, no. 3
PID:
20.500.12556/RUL-163535
UDC:
61-027.552
ISSN on article:
1846-9558
DOI:
10.2478/acph-2024-0030
COBISS.SI-ID:
206023171
Publication date in RUL:
08.10.2024
Views:
55
Downloads:
8
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Acta pharmaceutica
Shortened title:
Acta pharm.
Publisher:
Croatian Pharmaceutical Society
ISSN:
1846-9558
COBISS.SI-ID:
3817585
Licences
License:
CC BY-ND 4.0, Creative Commons Attribution-NoDerivatives 4.0 International
Link:
http://creativecommons.org/licenses/by-nd/4.0/
Description:
Under the NoDerivatives Creative Commons license one can take a work released under this license and re-distribute it, but it cannot be shared with others in adapted form, and credit must be provided to the author.
Secondary language
Language:
Slovenian
Keywords:
tiopurini
,
TPMT
,
NUDT15
,
terapevtsko spremljanje zdravil
,
personalizirana medicina
Projects
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
P1-0208
Name:
Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
I0-0022
Name:
Mreža raziskovalnih infrastrukturnih centrov Univerze v Ljubljani (MRIC UL)
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
I0-E011
Name:
Izvajanje mednarodnega infrastrukturnega projekta EATRIS
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back